Manila Bulletin
Duterte may get Sinopharm 2nd jab as FDA gives nod
President Rodrigo Duterte will receive his second dose of the Sinopharm COVID-19 vaccine.
This follows the Food and Drug Administration's (FDA) issuance of an Emergency Use Authorization (EUA) for Sinopharm vaccines.
Presidential Spokesperson Harry Roque confirmed that the President's second dose was pending the EUA.
Duterte received his first Sinopharm dose on May 3, prior to the vaccine securing an EUA.
Initially, the FDA had only issued a compassionate use license for 10,000 Sinopharm doses for the Presidential Security Group (PSG).
China had donated additional Sinopharm doses, on top of the initial 10,000 vials for PSG personnel.
President Duterte had previously ordered the pullout of Sinopharm vaccines on May 6 due to concerns over the lack of FDA clearance.
Topics in this story
Explore more stories about these topics.
🤖
This story was generated by AI to help you understand the key points. For more detailed coverage, please see the news articles from trusted media outlets below.
News Sources
See how different news organizations are covering this story. Below are the original articles from various Philippine news sources that contributed to this summary.
The Food and Drug Administration (FDA) has granted an emergency use authorization (EUA) to the Department of Health (DOH) to accept donations of the Sinopharm COVID-19 vaccine from China.
Read more →
President Rodrigo Duterte has directed local government units (LGUs) to actively locate individuals who have missed their second COVID-19 vaccine dose.
Read more →
President Rodrigo Duterte has approved the release of P2.5 billion from his contingency fund to purchase COVID-19 vaccines.
Read more →
President Rodrigo Duterte remains undecided about a potential vice presidential bid in the 2022 elections, with his focus currently on the country's COVID-19 vaccination program.
Read more →
President Rodrigo Duterte expressed optimism that the Philippines is nearing the end of the COVID-19 pandemic due to the arrival of substantial vaccine doses and the commencement of vaccinations for economic front-liners (A4 category).
Read more →